Replies to post #2840 on China Growth Stocks

[Potse]

RHGP($1.10)...pink sheet pharma/biotech.....

"Viking is best-known for bringing China pharma RHGP public."

Speaking of RHGP: IMO, the risk/reward on RHGP has just improved with the company filing its annual report today for the year ended October 2008. I think the possibility exists for some pretty sharp/explosive moves in the share price, if this particular filing is an indication of positive events to come.

Disclosed in the subsequent events section of the 10-K was this piece of information.....

On May 15, 2009, there is an agreement between Renhuang and Allied Merit International Investments, Inc. and Griffin Ventures Ltd (the “Investors”). The Investors agreed to pay Renhuang $ 1.5 million in exchange for an aggregate of 2,142,856 shares of the Company’s Common Stock and 1,071,428 Warrants with an exercise price of $0.875. The Company issued 2,142,856 shares on May 20, 2009 and received the $1.5 million on August 7, 2009.

This investment of money into RHGP suggests to me that there is a decent chance that the company will catch up on its SEC filings and probably upgrade to the bulletin board.

Using a fully-diluted share count of a little over 38M (includes the warrants mentioned above), RHGP's 2008 earnings came in at about .30 cents/shr. Book value was above .90/shr.

[Potse]

SBAT...picked up some more shares.....

Added some more shares of this shell at 23 cents. All things considered (share structure, valuation, ownership, risk/reward, etc.) SBAT continues to be among the most attractive shells in the market, IMO.

As I mentioned in the above post, as long as the Viking/SBAT agreement remains in place in which Viking absorbs all of SBAT's expenses until a change in ownership control, there is a decent chance at making nice money on this shell around this 20-30 cent area.

If RHGP steps up to the plate and does well in the coming weeks/months (as I am anticipating), that is something that could draw some additional attention to the SBAT shell.